Drug Trial Radar · NCT03308201
Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Oct 16, 2017
Primary completion
Jun 30, 2022
Study completion Mar 1, 2023
Sponsor
- Lead sponsor
- Tianjin Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of Hemay022 combined with endocrine therapy in the treatment of ER and HER2-positive metastatic or advanced breast cancer, and to establish OTR (best tolerated regimen). The second purpose of this study is to evaluate the pharmacokinetics and efficacy of Hemay022 in combination with exemestane, and the safety of Hemay022 in combination with letrozole or fulvestrant. The research will be divided into two parts. In the first part, 15 to 24 subjects will be enrolled to determine the safety and tolerability of combining Hemay022 with exemestane in patients with HER2-positive advanced breast cancer. The second part will enroll about 24-36 other subjects with ER and HER2-positive advanced breast cancer to better determine the tolerability and preliminary efficacy of Hemay022.
Conditions
- Breast Cancer
Interventions
Hemay022+exemestaneDrug
Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane. Part two: Hemay022 tablets combination with exemestane.
Hemay022+letrozoleDrug
Part two: Hemay022 combination with letrozole.
Hemay022+ fulvestrantDrug
Part two: Hemay022 combination with fulvestrant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: from baseline until 4 weeks after the study day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.